Amonafide
![]() | |
Systematic (IUPAC) name | |
---|---|
5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione | |
Clinical data | |
Identifiers | |
69408-81-7 | |
None | |
PubChem | CID 50515 |
ChemSpider |
45804 ![]() |
UNII |
1Q8D39N37L ![]() |
KEGG |
D10090 ![]() |
ChEMBL |
CHEMBL428676 ![]() |
Chemical data | |
Formula | C16H17N3O3 |
283.325 g/mol | |
SMILES
| |
| |
![]() |
Amonafide (originally AS1413) (INN, trade name Quinamed) is a drug that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and DNA intercalators.
It is being developed as an anti-cancer therapy by Antisoma.[1]
As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).[2]
References
- ↑ http://www.genengnews.com/news/bnitem.aspx?name=78979622
- ↑ http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"
External links
- Amonafide entry in the public domain NCI Dictionary of Cancer Terms
- Clinical trials of amonafide at ClinicalTrials.gov
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".